MedElevator
Войти в исследования European journal of internal medicine · 2026
Effects of urine uromodulin levels on the association between sodium intake and ambulatory blood pressure in individuals with chronic kidney disease.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Karagiannidis Artemios G, Baroutidou Amalia, Theodorakopoulou Marieta, Karkamani Eleni, Manti Sofia, Afkou Zoi, Vagdatli Eleni, Faitatzidou Danai, Giamalis Panagiotis, Papadopoulos Christodoulos, Sarafidis Pantelis
Аннотация
BACKGROUND: In CKD, hypertension is often accompanied by sodium sensitivity. Uromodulin promotes sodium sensitivity by activating tubular sodium transporters (NKCC2, NCC). In the general population, individuals with higher urine uromodulin have a positive association between 24-h urine sodium and 24-h BP, whereas those with lower uromodulin show a negative association between these parameters. Whether similar patterns occur in CKD remains unclear. This study evaluated the effect of urine uromodulin on the relationship between 24-h urine sodium excretion and 24-h BP in CKD patients.
METHODS: 130 patients with CKD G1-G5 on stable antihypertensive treatment underwent 24-h ambulatory BP monitoring and 24-h urine collections. Patients were divided into two groups using the median 24-h urine uromodulin. Associations between 24-h urine sodium excretion and 24-h BP were examined applying multivariable linear regression models.
RESULTS: Mean age was 62.6 ± 14.9 years and mean eGFR 49.0 ± 25.1mL/min/1.73m². 24-h SBP, DBP and urine sodium excretion did not differ across CKD stages, whereas urine uromodulin decreased significantly with advancing CKD (p < 0.001). In the multivariable linear regression models of the overall population, neither 24-h urine sodium nor urine uromodulin alone predicted 24-h SBP/DBP. However, in stratified models, higher 24-h urine sodium was associated with higher 24-h SBP (β=0.051, 95%CI:0.018-0.087, p = 0.005) and DBP (β=0.041, 95%CI:0.018-0.068, p = 0.002) only in the high-uromodulin group. In contrast, in the low-uromodulin group, no significant associations were observed. The β-coefficients for urine sodium differed significantly between uromodulin groups for both 24-h SBP and DBP models (p = 0.025 and p = 0.004 respectively).
CONCLUSIONS: In CKD, urine uromodulin modifies the association between dietary sodium intake and ambulatory BP. Patients with higher urine uromodulin show a positive association between 24-h sodium excretion and BP, whereas this finding is absent in those with lower uromodulin. These findings support urine uromodulin as a useful biomarker of sodium sensitivity in CKD.
CLINICAL TRIAL REGISTRATION NUMBER: NCT06363097 (ClinicalTrial.gov).
METHODS: 130 patients with CKD G1-G5 on stable antihypertensive treatment underwent 24-h ambulatory BP monitoring and 24-h urine collections. Patients were divided into two groups using the median 24-h urine uromodulin. Associations between 24-h urine sodium excretion and 24-h BP were examined applying multivariable linear regression models.
RESULTS: Mean age was 62.6 ± 14.9 years and mean eGFR 49.0 ± 25.1mL/min/1.73m². 24-h SBP, DBP and urine sodium excretion did not differ across CKD stages, whereas urine uromodulin decreased significantly with advancing CKD (p < 0.001). In the multivariable linear regression models of the overall population, neither 24-h urine sodium nor urine uromodulin alone predicted 24-h SBP/DBP. However, in stratified models, higher 24-h urine sodium was associated with higher 24-h SBP (β=0.051, 95%CI:0.018-0.087, p = 0.005) and DBP (β=0.041, 95%CI:0.018-0.068, p = 0.002) only in the high-uromodulin group. In contrast, in the low-uromodulin group, no significant associations were observed. The β-coefficients for urine sodium differed significantly between uromodulin groups for both 24-h SBP and DBP models (p = 0.025 and p = 0.004 respectively).
CONCLUSIONS: In CKD, urine uromodulin modifies the association between dietary sodium intake and ambulatory BP. Patients with higher urine uromodulin show a positive association between 24-h sodium excretion and BP, whereas this finding is absent in those with lower uromodulin. These findings support urine uromodulin as a useful biomarker of sodium sensitivity in CKD.
CLINICAL TRIAL REGISTRATION NUMBER: NCT06363097 (ClinicalTrial.gov).